 | • レポートコード：MRC2-11QY04369 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、94ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は原発性アルドステロン症のグローバル市場について調査・分析したレポートです。種類別（心臓発作、腎不全、脳卒中）市場規模、用途別（病院・診療所、研究機関、学術機関）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別原発性アルドステロン症の競争状況、市場シェア ・世界の原発性アルドステロン症市場：種類別市場規模 2015年-2020年（心臓発作、腎不全、脳卒中） ・世界の原発性アルドステロン症市場：種類別市場規模予測 2021年-2026年（心臓発作、腎不全、脳卒中） ・世界の原発性アルドステロン症市場：用途別市場規模 2015年-2020年（病院・診療所、研究機関、学術機関） ・世界の原発性アルドステロン症市場：用途別市場規模予測 2021年-2026年（病院・診療所、研究機関、学術機関） ・北米の原発性アルドステロン症市場分析：米国、カナダ ・ヨーロッパの原発性アルドステロン症市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの原発性アルドステロン症市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の原発性アルドステロン症市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの原発性アルドステロン症市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Pfizer、Sun Pharmaceutical Industries、Bristol Laboratories、CMP Pharma、Koninklijke Philips、GE Healthcare、Siemens、Shimadzu Corporation、Canon ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Primary aldosteronism refers to the excess production of the hormone aldosterone from the adrenal glands, resulting in low renin levels. This abnormality is caused by hyperplasia or tumors. Many suffer from fatigue, potassium deficiency and high blood pressure which may cause poor vision, confusion or headaches.
The treatment for hyperaldosteronism depends on the underlying cause. In people with a single benign tumor (adenoma), surgical removal (adrenalectomy) may be curative. This is usually performed laparoscopically, through several very small incisions. For people with hyperplasia of both glands, successful treatment is often achieved with spironolactone or eplerenone, drugs that block the effect of aldosterone.
Market Analysis and Insights: Global Primary Aldosteronism Market
The global Primary Aldosteronism market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Primary Aldosteronism Scope and Market Size
Primary Aldosteronism market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Primary Aldosteronism market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
The key players covered in this study
Pfizer
Sun Pharmaceutical Industries
Bristol Laboratories
CMP Pharma
Koninklijke Philips
GE Healthcare
Siemens
Shimadzu Corporation
Canon
Market segment by Type, the product can be split into
Heart Attack
Kidney Failure
Stroke
Market segment by Application, split into
Hospitals & Clinics
Research Organization
Academic Institutes
Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Primary Aldosteronism Revenue
1.4 Market by Type
1.4.1 Global Primary Aldosteronism Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Heart Attack
1.4.3 Kidney Failure
1.4.4 Stroke
1.5 Market by Application
1.5.1 Global Primary Aldosteronism Market Share by Application: 2020 VS 2026
1.5.2 Hospitals & Clinics
1.5.3 Research Organization
1.5.4 Academic Institutes
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Primary Aldosteronism Market Perspective (2015-2026)
2.2 Global Primary Aldosteronism Growth Trends by Regions
2.2.1 Primary Aldosteronism Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Primary Aldosteronism Historic Market Share by Regions (2015-2020)
2.2.3 Primary Aldosteronism Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Primary Aldosteronism Market Growth Strategy
2.3.6 Primary Interviews with Key Primary Aldosteronism Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Primary Aldosteronism Players by Market Size
3.1.1 Global Top Primary Aldosteronism Players by Revenue (2015-2020)
3.1.2 Global Primary Aldosteronism Revenue Market Share by Players (2015-2020)
3.1.3 Global Primary Aldosteronism Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Primary Aldosteronism Market Concentration Ratio
3.2.1 Global Primary Aldosteronism Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Primary Aldosteronism Revenue in 2019
3.3 Primary Aldosteronism Key Players Head office and Area Served
3.4 Key Players Primary Aldosteronism Product Solution and Service
3.5 Date of Enter into Primary Aldosteronism Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Primary Aldosteronism Historic Market Size by Type (2015-2020)
4.2 Global Primary Aldosteronism Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Primary Aldosteronism Market Size by Application (2015-2020)
5.2 Global Primary Aldosteronism Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Primary Aldosteronism Market Size (2015-2020)
6.2 Primary Aldosteronism Key Players in North America (2019-2020)
6.3 North America Primary Aldosteronism Market Size by Type (2015-2020)
6.4 North America Primary Aldosteronism Market Size by Application (2015-2020)
7 Europe
7.1 Europe Primary Aldosteronism Market Size (2015-2020)
7.2 Primary Aldosteronism Key Players in Europe (2019-2020)
7.3 Europe Primary Aldosteronism Market Size by Type (2015-2020)
7.4 Europe Primary Aldosteronism Market Size by Application (2015-2020)
8 China
8.1 China Primary Aldosteronism Market Size (2015-2020)
8.2 Primary Aldosteronism Key Players in China (2019-2020)
8.3 China Primary Aldosteronism Market Size by Type (2015-2020)
8.4 China Primary Aldosteronism Market Size by Application (2015-2020)
9 Japan
9.1 Japan Primary Aldosteronism Market Size (2015-2020)
9.2 Primary Aldosteronism Key Players in Japan (2019-2020)
9.3 Japan Primary Aldosteronism Market Size by Type (2015-2020)
9.4 Japan Primary Aldosteronism Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Primary Aldosteronism Market Size (2015-2020)
10.2 Primary Aldosteronism Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Primary Aldosteronism Market Size by Type (2015-2020)
10.4 Southeast Asia Primary Aldosteronism Market Size by Application (2015-2020)
11 India
11.1 India Primary Aldosteronism Market Size (2015-2020)
11.2 Primary Aldosteronism Key Players in India (2019-2020)
11.3 India Primary Aldosteronism Market Size by Type (2015-2020)
11.4 India Primary Aldosteronism Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Primary Aldosteronism Market Size (2015-2020)
12.2 Primary Aldosteronism Key Players in Central & South America (2019-2020)
12.3 Central & South America Primary Aldosteronism Market Size by Type (2015-2020)
12.4 Central & South America Primary Aldosteronism Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Pfizer
13.1.1 Pfizer Company Details
13.1.2 Pfizer Business Overview
13.1.3 Pfizer Primary Aldosteronism Introduction
13.1.4 Pfizer Revenue in Primary Aldosteronism Business (2015-2020))
13.1.5 Pfizer Recent Development
13.2 Sun Pharmaceutical Industries
13.2.1 Sun Pharmaceutical Industries Company Details
13.2.2 Sun Pharmaceutical Industries Business Overview
13.2.3 Sun Pharmaceutical Industries Primary Aldosteronism Introduction
13.2.4 Sun Pharmaceutical Industries Revenue in Primary Aldosteronism Business (2015-2020)
13.2.5 Sun Pharmaceutical Industries Recent Development
13.3 Bristol Laboratories
13.3.1 Bristol Laboratories Company Details
13.3.2 Bristol Laboratories Business Overview
13.3.3 Bristol Laboratories Primary Aldosteronism Introduction
13.3.4 Bristol Laboratories Revenue in Primary Aldosteronism Business (2015-2020)
13.3.5 Bristol Laboratories Recent Development
13.4 CMP Pharma
13.4.1 CMP Pharma Company Details
13.4.2 CMP Pharma Business Overview
13.4.3 CMP Pharma Primary Aldosteronism Introduction
13.4.4 CMP Pharma Revenue in Primary Aldosteronism Business (2015-2020)
13.4.5 CMP Pharma Recent Development
13.5 Koninklijke Philips
13.5.1 Koninklijke Philips Company Details
13.5.2 Koninklijke Philips Business Overview
13.5.3 Koninklijke Philips Primary Aldosteronism Introduction
13.5.4 Koninklijke Philips Revenue in Primary Aldosteronism Business (2015-2020)
13.5.5 Koninklijke Philips Recent Development
13.6 GE Healthcare
13.6.1 GE Healthcare Company Details
13.6.2 GE Healthcare Business Overview
13.6.3 GE Healthcare Primary Aldosteronism Introduction
13.6.4 GE Healthcare Revenue in Primary Aldosteronism Business (2015-2020)
13.6.5 GE Healthcare Recent Development
13.7 Siemens
13.7.1 Siemens Company Details
13.7.2 Siemens Business Overview
13.7.3 Siemens Primary Aldosteronism Introduction
13.7.4 Siemens Revenue in Primary Aldosteronism Business (2015-2020)
13.7.5 Siemens Recent Development
13.8 Shimadzu Corporation
13.8.1 Shimadzu Corporation Company Details
13.8.2 Shimadzu Corporation Business Overview
13.8.3 Shimadzu Corporation Primary Aldosteronism Introduction
13.8.4 Shimadzu Corporation Revenue in Primary Aldosteronism Business (2015-2020)
13.8.5 Shimadzu Corporation Recent Development
13.9 Canon
13.9.1 Canon Company Details
13.9.2 Canon Business Overview
13.9.3 Canon Primary Aldosteronism Introduction
13.9.4 Canon Revenue in Primary Aldosteronism Business (2015-2020)
13.9.5 Canon Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
Table 1. Primary Aldosteronism Key Market Segments
Table 2. Key Players Covered: Ranking by Primary Aldosteronism Revenue
Table 3. Ranking of Global Top Primary Aldosteronism Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Primary Aldosteronism Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Heart Attack
Table 6. Key Players of Kidney Failure
Table 7. Key Players of Stroke
Table 8. Global Primary Aldosteronism Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Primary Aldosteronism Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Primary Aldosteronism Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Primary Aldosteronism Market Share by Regions (2015-2020)
Table 12. Global Primary Aldosteronism Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Primary Aldosteronism Market Share by Regions (2021-2026)
Table 14. Market Top Trends
Table 15. Key Drivers: Impact Analysis
Table 16. Key Challenges
Table 17. Primary Aldosteronism Market Growth Strategy
Table 18. Main Points Interviewed from Key Primary Aldosteronism Players
Table 19. Global Primary Aldosteronism Revenue by Players (2015-2020) (Million US$)
Table 20. Global Primary Aldosteronism Market Share by Players (2015-2020)
Table 21. Global Top Primary Aldosteronism Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Primary Aldosteronism as of 2019)
Table 22. Global Primary Aldosteronism by Players Market Concentration Ratio (CR5 and HHI)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Primary Aldosteronism Product Solution and Service
Table 25. Date of Enter into Primary Aldosteronism Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Primary Aldosteronism Market Size by Type (2015-2020) (Million US$)
Table 28. Global Primary Aldosteronism Market Size Share by Type (2015-2020)
Table 29. Global Primary Aldosteronism Revenue Market Share by Type (2021-2026)
Table 30. Global Primary Aldosteronism Market Size Share by Application (2015-2020)
Table 31. Global Primary Aldosteronism Market Size by Application (2015-2020) (Million US$)
Table 32. Global Primary Aldosteronism Market Size Share by Application (2021-2026)
Table 33. North America Key Players Primary Aldosteronism Revenue (2019-2020) (Million US$)
Table 34. North America Key Players Primary Aldosteronism Market Share (2019-2020)
Table 35. North America Primary Aldosteronism Market Size by Type (2015-2020) (Million US$)
Table 36. North America Primary Aldosteronism Market Share by Type (2015-2020)
Table 37. North America Primary Aldosteronism Market Size by Application (2015-2020) (Million US$)
Table 38. North America Primary Aldosteronism Market Share by Application (2015-2020)
Table 39. Europe Key Players Primary Aldosteronism Revenue (2019-2020) (Million US$)
Table 40. Europe Key Players Primary Aldosteronism Market Share (2019-2020)
Table 41. Europe Primary Aldosteronism Market Size by Type (2015-2020) (Million US$)
Table 42. Europe Primary Aldosteronism Market Share by Type (2015-2020)
Table 43. Europe Primary Aldosteronism Market Size by Application (2015-2020) (Million US$)
Table 44. Europe Primary Aldosteronism Market Share by Application (2015-2020)
Table 45. China Key Players Primary Aldosteronism Revenue (2019-2020) (Million US$)
Table 46. China Key Players Primary Aldosteronism Market Share (2019-2020)
Table 47. China Primary Aldosteronism Market Size by Type (2015-2020) (Million US$)
Table 48. China Primary Aldosteronism Market Share by Type (2015-2020)
Table 49. China Primary Aldosteronism Market Size by Application (2015-2020) (Million US$)
Table 50. China Primary Aldosteronism Market Share by Application (2015-2020)
Table 51. Japan Key Players Primary Aldosteronism Revenue (2019-2020) (Million US$)
Table 52. Japan Key Players Primary Aldosteronism Market Share (2019-2020)
Table 53. Japan Primary Aldosteronism Market Size by Type (2015-2020) (Million US$)
Table 54. Japan Primary Aldosteronism Market Share by Type (2015-2020)
Table 55. Japan Primary Aldosteronism Market Size by Application (2015-2020) (Million US$)
Table 56. Japan Primary Aldosteronism Market Share by Application (2015-2020)
Table 57. Southeast Asia Key Players Primary Aldosteronism Revenue (2019-2020) (Million US$)
Table 58. Southeast Asia Key Players Primary Aldosteronism Market Share (2019-2020)
Table 59. Southeast Asia Primary Aldosteronism Market Size by Type (2015-2020) (Million US$)
Table 60. Southeast Asia Primary Aldosteronism Market Share by Type (2015-2020)
Table 61. Southeast Asia Primary Aldosteronism Market Size by Application (2015-2020) (Million US$)
Table 62. Southeast Asia Primary Aldosteronism Market Share by Application (2015-2020)
Table 63. India Key Players Primary Aldosteronism Revenue (2019-2020) (Million US$)
Table 64. India Key Players Primary Aldosteronism Market Share (2019-2020)
Table 65. India Primary Aldosteronism Market Size by Type (2015-2020) (Million US$)
Table 66. India Primary Aldosteronism Market Share by Type (2015-2020)
Table 67. India Primary Aldosteronism Market Size by Application (2015-2020) (Million US$)
Table 68. India Primary Aldosteronism Market Share by Application (2015-2020)
Table 69. Central & South America Key Players Primary Aldosteronism Revenue (2019-2020) (Million US$)
Table 70. Central & South America Key Players Primary Aldosteronism Market Share (2019-2020)
Table 71. Central & South America Primary Aldosteronism Market Size by Type (2015-2020) (Million US$)
Table 72. Central & South America Primary Aldosteronism Market Share by Type (2015-2020)
Table 73. Central & South America Primary Aldosteronism Market Size by Application (2015-2020) (Million US$)
Table 74. Central & South America Primary Aldosteronism Market Share by Application (2015-2020)
Table 75. Pfizer Company Details
Table 76. Pfizer Business Overview
Table 77. Pfizer Product
Table 78. Pfizer Revenue in Primary Aldosteronism Business (2015-2020) (Million US$)
Table 79. Pfizer Recent Development
Table 80. Sun Pharmaceutical Industries Company Details
Table 81. Sun Pharmaceutical Industries Business Overview
Table 82. Sun Pharmaceutical Industries Product
Table 83. Sun Pharmaceutical Industries Revenue in Primary Aldosteronism Business (2015-2020) (Million US$)
Table 84. Sun Pharmaceutical Industries Recent Development
Table 85. Bristol Laboratories Company Details
Table 86. Bristol Laboratories Business Overview
Table 87. Bristol Laboratories Product
Table 88. Bristol Laboratories Revenue in Primary Aldosteronism Business (2015-2020) (Million US$)
Table 89. Bristol Laboratories Recent Development
Table 90. CMP Pharma Company Details
Table 91. CMP Pharma Business Overview
Table 92. CMP Pharma Product
Table 93. CMP Pharma Revenue in Primary Aldosteronism Business (2015-2020) (Million US$)
Table 94. CMP Pharma Recent Development
Table 95. Koninklijke Philips Company Details
Table 96. Koninklijke Philips Business Overview
Table 97. Koninklijke Philips Product
Table 98. Koninklijke Philips Revenue in Primary Aldosteronism Business (2015-2020) (Million US$)
Table 99. Koninklijke Philips Recent Development
Table 100. GE Healthcare Company Details
Table 101. GE Healthcare Business Overview
Table 102. GE Healthcare Product
Table 103. GE Healthcare Revenue in Primary Aldosteronism Business (2015-2020) (Million US$)
Table 104. GE Healthcare Recent Development
Table 105. Siemens Company Details
Table 106. Siemens Business Overview
Table 107. Siemens Product
Table 108. Siemens Revenue in Primary Aldosteronism Business (2015-2020) (Million US$)
Table 109. Siemens Recent Development
Table 110. Shimadzu Corporation Business Overview
Table 111. Shimadzu Corporation Product
Table 112. Shimadzu Corporation Company Details
Table 113. Shimadzu Corporation Revenue in Primary Aldosteronism Business (2015-2020) (Million US$)
Table 114. Shimadzu Corporation Recent Development
Table 115. Canon Company Details
Table 116. Canon Business Overview
Table 117. Canon Product
Table 118. Canon Revenue in Primary Aldosteronism Business (2015-2020) (Million US$)
Table 119. Canon Recent Development
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Primary Aldosteronism Market Share by Type: 2020 VS 2026
Figure 2. Heart Attack Features
Figure 3. Kidney Failure Features
Figure 4. Stroke Features
Figure 5. Global Primary Aldosteronism Market Share by Application: 2020 VS 2026
Figure 6. Hospitals & Clinics Case Studies
Figure 7. Research Organization Case Studies
Figure 8. Academic Institutes Case Studies
Figure 9. Primary Aldosteronism Report Years Considered
Figure 10. Global Primary Aldosteronism Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Primary Aldosteronism Market Share by Regions: 2020 VS 2026
Figure 12. Global Primary Aldosteronism Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Primary Aldosteronism Market Share by Players in 2019
Figure 15. Global Top Primary Aldosteronism Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Primary Aldosteronism as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Primary Aldosteronism Revenue in 2019
Figure 17. North America Primary Aldosteronism Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Primary Aldosteronism Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Primary Aldosteronism Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Primary Aldosteronism Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Primary Aldosteronism Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Primary Aldosteronism Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Primary Aldosteronism Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed
心不全監視ソフトウェアの世界市場（～2026年） Market Analysis and Insights: Global Heart Failure Mornitoring Software Market The global Heart Failure Mornitoring Software market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Heart Failure Mornitoring Software Scope and …- 急性心不全（AHF）治療薬の世界市場（～2026年） Market Analysis and Insights: Global Acute Heart Failure (AHF) Therapeutics Market The global Acute Heart Failure (AHF) Therapeutics market size is projected to reach US$ 336 million by 2026, from US$ 262.2 million in 2020, at a CAGR of 26.8%% during 2021-2026. Global Acute Heart Failure (AHF) Thera…
- うっ血性心不全（CHF）の世界市場（～2026年） Market Analysis and Insights: Global Congestive Heart Failure (CHF) Market The global Congestive Heart Failure (CHF) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Congestive Heart Failure (CHF) Scope and Market Size …
- うっ血性心不全治療薬の世界市場（～2026年） Market Analysis and Insights: Global Congestive Heart Failure Drugs Market The global Congestive Heart Failure Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Congestive Heart Failure Drugs Scope and Market Size …
- 急性腎不全治療薬の世界市場（～2026年） Acute renal failure is a sudden loss of kidney’s ability to eliminate excess fluids, salts and metabolic waste from the body. It leads to accumulation of metabolic waste and electrolytes in the body which can be life-threatening. Kidney eliminates creatinine (Metabolic waste) from the body. Acute re…